‘Silo­ing is just so out­dat­ed’: New $350M VC fund aims to dig­i­tize life sci­ences

As tech­nol­o­gy in­creas­ing­ly helps find drug tar­gets, en­hance the di­ag­no­sis of dis­eases, speed up the test­ing of new ther­a­peu­tics and es­sen­tial­ly an­gle its way in­to every cor­ner of life sci­ences, en­tre­pre­neurs will need a new type of VC firm.

At least, that’s the think­ing be­hind the lat­est fund to drop. Di­men­sion, out of New York and San Fran­cis­co, launched Wednes­day with $350 mil­lion to bankroll a cou­ple dozen star­tups, some of which it will help form. The port­fo­lio al­ready in­cludes Kalei­do­scope, mak­er of a tool to help teams keep tabs on R&D, and Enve­da Bio­sciences, which is near­ing the clin­ic.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN